Business context and reporting period
This is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2011. The filing identifies ZIOPHARM—not Alaunos Therapeutics—as the registrant; investors should confirm the requested company mapping. ZIOPHARM was a development-stage biopharmaceutical company with oncology drug candidates in clinical development and no approved products or product sales.
Financial performance and position
| Metric | Q3 2011 | Nine months 2011 | Comparable 2010 |
|---|---|---|---|
| Revenue | $0.2 million | $0.467 million | $0 in both periods |
| Operating expenses | $14.4 million | $55.5 million | $8.5 million and $18.2 million |
| Operating loss | $14.2 million | $55.0 million | $8.5 million and $18.2 million |
| Net loss | $0.8 million | $50.5 million | $12.2 million and $20.8 million |
| Operating cash flow | Not separately provided | $(25.1) million | $(13.9) million |
- Q3 net loss was substantially reduced by a $13.4 million noncash gain from the change in fair value of warrant liabilities. For the nine months, the corresponding gain was $4.4 million. These gains are not operating revenue or cash generation.
- Nine-month R&D expense was $44.4 million, up from $9.9 million, including a one-time $17.5 million noncash charge tied to Intrexon shares and increased clinical and development activity. G&A was $11.0 million, versus $8.3 million.
- Cash and cash equivalents were $118.9 million at September 30, 2011, up from $60.4 million at year-end 2010. Working capital was $108.6 million. Financing activities provided $84.4 million, including $71.2 million of proceeds from equity and warrant-related financing.
- Total liabilities were $38.2 million, including $22.6 million of warrant liabilities and $4.5 million of deferred revenue. The filing reports no conventional borrowings. Contractual obligations totaled $19.2 million, including $11.9 million of clinical-trial milestone payments.
- Common shares outstanding increased to 68.45 million from 48.47 million at year-end. The nine-month loss per share was $0.77, compared with $0.48 in 2010.
Material changes versus prior period
Revenue began under the Solasia collaboration, which contributed $0.467 million in the first nine months. Operating expenses and cash use increased as ZIOPHARM expanded palifosfamide Phase 3 work and Intrexon-related programs. The company raised capital through a February public offering and other share issuances, substantially increasing cash and shares outstanding. Reported net loss comparisons were also affected by year-to-year movements in the noncash fair value of warrants.
Outlook, commentary and risks
- Management expected existing cash to fund operations into early 2013, but stated additional financing would be needed for longer-term clinical development and there was no assurance it could be obtained on acceptable terms.
- For the next 12 months, management forecast approximately $83.5 million of R&D expense and $16.3 million of G&A expense; actual costs could differ materially.
- Key programs included the PICASSO 3 Phase 3 palifosfamide trial, oral darinaparsin, indibulin, and Intrexon-linked ZIN-CTI-001 and ZIN-ATI-001. Management expected PICASSO 3 enrollment to complete early in Q1 2012 and progression-free-survival results in the second half of 2012, subject to enrollment and other risks. The trial had experienced slower-than-expected startup enrollment and a limited doxorubicin supply.
- Clinical failure, delays, safety or regulatory issues, rising trial costs, dependence on third parties, intellectual-property challenges, and the need for further capital could delay or curtail development. The company had not generated product revenue and anticipated continued losses.
- The filing reported effective disclosure controls, no material change in internal control over financial reporting, no material legal proceedings, and no material subsequent events identified through issuance.
Investor verification priorities
- Confirm the registrant and corporate-history link between ZIOPHARM and Alaunos Therapeutics before attributing these results to the requested company.
- Track cash burn, financing needs, and whether the early-2013 cash runway assumptions remained achievable.
- Verify PICASSO 3 enrollment, drug supply, timing, and eventual trial results against management’s forecasts.
- Separate operating performance and cash flow from noncash warrant revaluation gains and the $17.5 million Intrexon-related charge.
- Review share dilution, warrant exposure, the remaining Intrexon equity purchase commitment, and contractual milestone obligations.